Market Newsdesk

INDIANAPOLIS
, June 23, 2025 /PRNewswire/ — The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock.

The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly’s current beliefs and expectations. However, there are significant risks and uncertainties in pharmaceutical research and development, as well as in business development activities and capital allocation strategies related to the company’s business and actual results may differ materially due to various factors. For further discussion of risks and uncertainties relevant to Lilly’s business that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-declares-third-quarter-2025-dividend-302488416.html

SOURCE Eli Lilly and Company

CHARLOTTE, N.C.
, June 23, 2025 /PRNewswire/ — As high temperatures increase, Duke Energy is urging customers in the Carolinas to reduce their energy use during periods of peak demand today, June 23 from 3-8 p.m. to help lessen the energy demand on the power grid and reduce the potential of isolated power outages.

As we continue to manage available power supplies, protect the grid and maintain normal operations, here are some simple ways customers can help:

• At home, raise the temperature to the highest comfortable setting. Keep in mind: Your system will run longer the hotter it is outside – even if your thermostat setting never changes. Postpone laundry until later in the evening or tomorrow morning.
• Avoid prolonged use of your electric range/oven, which can heat up the house, making your AC work harder, using more energy.
• Avoid using appliances such as washing machines, dryers and dishwashers during the high-demand hours noted above.
• Consider grilling outdoors to keep indoor temperatures lower and reduce energy use from electric stovetops and ovens.
• Turn off any unnecessary appliances, unused plug-ins and lights.

“We deeply appreciate our customers’ cooperation, patience and understanding as we work to help ensure the stability and reliability of the system,” said Ben Harrison, Duke Energy vice president of grid operations – planning and operations. “We understand that reducing electricity use during these hours can be inconvenient, but our customers’ actions make a significant difference for all.”

Duke Energy 

Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America’s largest energy holding companies. The company’s electric utilities serve 8.6 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,100 megawatts of energy capacity. Its natural gas utilities serve 1.7 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky. 

Duke Energy is executing an ambitious energy transition, keeping customer reliability and value at the forefront as it builds a smarter energy future. The company is investing in major electric grid upgrades and cleaner generation, including natural gas, nuclear, renewables and energy storage. 

More information is available at duke-energy.com and the Duke Energy News Center. Follow Duke Energy on X, LinkedIn, Instagram and Facebook, and visit illumination for stories about the people and innovations powering our energy transition. 

24-Hour: 800.559.3853

View original content to download multimedia:https://www.prnewswire.com/news-releases/duke-energy-urges-north-carolina-and-south-carolina-customers-to-reduce-electric-usage-302488409.html

SOURCE Duke Energy

HONG KONG
, June 23, 2025 /PRNewswire/ — QMMM Holdings Limited (NASDAQ: QMMM) (the “Company” or “QMMM”), a digital media advertising, virtual avatar & virtual apparel technology service provider in Hong Kong, today announced the closing of its best efforts public offering of 40,000,000 ordinary shares at a public offering price of $0.20 per ordinary share.

Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be $8 million.

Pacific Century Securities LLC and Revere Securities LLC acted as co-placement agents in connection with this offering.

The securities described above were offered pursuant to a registration statement on Form F-1, as amended (File No. 333-287066) (the “Registration Statement”), originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 8, 2025. The Form F-1 was declared effective on June 20, 2025. The final prospectus was filed on June 20, 2025.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About 
QMMM Holdings Limited

QMMM Holdings Limited (the “Company”) is an award-winning digital advertising and marketing production services company. Through its operating subsidiaries ManyMany Creations Limited and Quantum Matrix Limited in Hong Kong, the Company has used interactive design, animation, art-tech and virtual technologies in over 500 commercial campaigns. The Company has worked with large domestic and international banks, real estate developers, world famous amusement park, top international athletic apparel and footwear brands and luxury cosmetic products and international brands for their advertising and creation work in Hong Kong. Standing prominently in Hong Kong for over 18 years in the industry, with top creativity, premium account servicing, and ever-advancing tech R&D, the Company continues to be one of the top premium choices for enterprises and multinational enterprises looking for large scale content-heavy and tech-integrated campaigns. The clients of the Company include local and international banks, real-estate developers, luxury brands, high fashion houses, and theme parks. 

Safe Harbor Statement

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to satisfy the closing conditions related to the offering, our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.

Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

For enquiry, please contact:

QMMM Holdings Limited
Unit 1301, Block C,
Sea View Estate,
8 Watson Road,
Tin Hau, Hong Kong
Phone: +852 3549 6889
Email: [email protected]

 

View original content:https://www.prnewswire.com/news-releases/qmmm-announces-closing-of-8-million-public-offering-of-ordinary-shares-302488408.html

SOURCE QMMM HOLDINGS LIMITED

–  ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi^® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination

–  ATNM-400 is more efficacious than both Pluvicto^® (177-Lu-PSMA-617) and Ac-225-PSMA-617 targeted radiotherapy in prostate cancer in vitro and in vivo models and overcome resistance in prostate cancer tumors that failed Pluvicto^® therapy

–  ATNM-400’s target is highly differentiated from PSMA as it is implicated in disease biology, contributing to disease progression, faster progression to castration resistance and poorer survival outcomes with target expression reported following androgen receptor inhibitor and PSMA radiotherapy

–  Data further supports ATNM-400’s potential to address critical gaps in prostate cancer treatment as a monotherapy or in sequence with other therapeutic modalities

NEW YORK
, June 23, 2025 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported new preclinical data from its first-in-class, non-PSMA targeting radiotherapy prostate cancer candidate ATNM-400, that leverages the potent alpha-particle emitter Actinium-225 (Ac-225) isotope, at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting being held June 21^st – 24^th, 2025, in New Orleans, Louisiana. The data presented at SNMMI showed ATNM-400 has superior potency compared Xtandi^® (enzalutamide) and is highly efficacious in Xtandi^® resistant prostate models. Xtandi is an androgen receptor inhibitor (ARPI) therapy developed and marketed by Astellas and Pfizer that is approved for three stages of prostate cancer and generated sales of $5.9 billion in 2024. Actinium also presented additional new data showing ATNM-400 is more efficacious than PSMA-617 labeled with both Lutetium-177 (Lu-177) and Ac-225 and that ATNM-400 also overcomes resistance to Pluvicto^® (Lu-177-PSMA-617). Pluvicto^® is developed and marketed by Novartis and generated sales of $1.4 billion in 2024. ATNM-400 represents a transformational therapeutic candidate being developed to overcome limitations of current prostate cancer therapies such as Xtandi^® and Pluvicto^® and improve outcomes over what is currently achievable. Key data and highlights from the ATNM-400 SNMMI presentation include: 

ATNM-400 Target Expression Profile and Disease Biology

• The ATNM-400 target is implicated in prostate cancer disease biology and contributes directly to disease progression, with expression correlating with shorter time to castration resistance and poorer survival in castrate resistant prostate cancer (CRPC) patients making it differentiated from PSMA, which serves primarily as a surface marker
• The target for ATNM-400 is also reported to be elevated in prostate cancer patients who develop resistance to the ARPI therapy Xtandi^®
• ATNM-400 shows consistent tumor uptake, rapid clearance from the blood and clearance from vital organs including intestines, liver, and kidneys
• Target expression is retained post Pluvicto^® treatment in prostate cancer models

ATNM-400 Compared to Xtandi^® (enzalutamide) 

• ATNM-400 exhibited potent killing of all Xtandi^® resistant prostate cancer cells that remained following treatment with Xtandi^®, with Xtandi^® only killing 50% of the resistant prostate cancer cells
• ATNM-400 monotherapy and in combination with Xtandi^® had superior anti-tumor efficacy in vivo compared to Xtandi alone in a prostate cancer model; all treatments were well-tolerated with no change in body weight
• ATNM-400 inhibited tumor growth of Xtandi^® resistant tumors whereas re-treatment with Pluvicto^® or additional enzalutamide did not

ATNM-400 Compared to PSMA targeted Radiotherapy

• ATNM-400 was more potent than both Pluvicto^® (177Lu-PSMA-617) and 225Ac-PSMA-617 in prostate cancer cell killing
• At therapeutically relevant doses, ATNM-400 exhibited more efficacious tumor growth inhibition compared to both Pluvicto^® and 225Ac-PSMA-617 in prostate cancer in vivo model
• As previously reported, ATNM-400 was able to overcome Pluvicto^® resistance, halting tumor growth in prostate cancer tumors that failed Pluvicto therapy and producing potent tumor cell killing

Sandesh Seth, Actinium’s Chairman and CEO, said, “We are committed to advancing ATNM-400 to address the high unmet needs that remain in prostate cancer. These new data presented at SNMMI demonstrate the therapeutic potential of ATNM-400 as both a monotherapy and in combination with both androgen receptor inhibitors and PSMA radiotherapy, two leading prostate cancer treatment modalities. With ATNM-400’s target being a disease-driving protein involved in tumor progression and therapeutic resistance combined with the potency and precision of the Ac-225 isotope payload, we believe ATNM-400 has a transformational profile rooted in prostate cancer disease biology, which is strongly supported by our data. We are thrilled to highlight ATNM-400’s first-in-class data at SNMMI and highly encouraged by the strong interest from KOL’s across the prostate cancer and nuclear medicine communities. As Actinium continues to advance our efforts with novel targeted radiotherapies, ATNM-400 is the ideal cornerstone of our emerging solid tumor pipeline.”

The ATNM-400 SNMII presentation is available for viewing on the Presentations & Webinars page of Actinium’s website HERE.

Title: First-in-class antibody radioconjugate ATNM-400 exhibits potent anti-tumor activity and overcomes resistance to enzalutamide and 177Lu-PSMA-617 in prostate cancer models

About ATNM-400

ATNM-400 is a highly innovative, first-in-class prostate cancer candidate in comparison to Pluvicto and the majority of radiotherapies in development for prostate cancer which target PSMA and are either non-differentiated or barely differentiated, as it targets a distinct non-PSMA receptor. The receptor specifically targeted by ATNM-400 is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), contributes directly to disease progression and poorer survival outcomes, and continues to be expressed at a high level even after androgen receptor inhibitor and Pluvicto treatment. ATNM-400 leverages the alpha-particle emitter Ac-225, which is more potent than Lu-177, can cause lethal irreversible double-stranded DNA breaks, and has a shorter path length that could result in fewer off-target effects.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA^® and OPDIVO^® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. ATNM-400 is Actinium’s novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer, which is supported by preclinical data demonstrating higher efficacy than Xtandi (androgen receptor inhibitor) and Pluvicto (PSMA-617-Lutetium-177) and potent efficacy in prostate cancer models resistant to both therapies. Iomab-ACT, Actinium’s next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company’s R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/

Forward-Looking Statements

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors:

[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-highlights-expanded-data-set-for-atnm-400-in-prostate-cancer-demonstrating-superior-efficacy-to-enzalutamide-and-ability-to-overcome-resistance-to-arpi-therapy-and-psma-ac-225lu-177-labelled-radiotherapy-at-the-society-o-302488334.html

SOURCE Actinium Pharmaceuticals, Inc.

ORLANDO, Fla.
, June 23, 2025 /PRNewswire/ — Buffalo Lodging Associates, LLC, proudly announces the completion of an extensive renovation at the four-story, 99-suite Homewood Suites by Hilton Orlando – UCF Area, located at 3028 N. Alafaya Trail. The property is now welcoming guests with a revitalized look and feel that enhances both comfort and style. A new exterior paint scheme paired with elegant stone accents sets the tone from the moment you arrive. The refreshed lobby and public spaces showcase a calming palette of blue and neutral tones, creating a serene and inviting ambiance. New furnishings and thoughtfully designed seating areas provide the perfect setting for relaxation or casual gatherings. Each spacious suite has been upgraded with contemporary furniture, new carpeting, modern wall coverings, updated artwork, and bathrooms—offering guests an elevated experience that truly feels like a home away from home.

“The completion of our recent renovation represents a significant investment in our continued commitment to excellence,” said Steffi Snelling, General Manager of Homewood Suites by Hilton Orlando – UCF Area. “We are proud to offer an enhanced guest experience that reflects the comfort, service, and convenience synonymous with the Homewood Suites brand. The updated design and amenities create a warm, contemporary environment that meets the evolving needs of today’s travelers.”

At Homewood Suites by Hilton Orlando – UCF Area, guests enjoy apartment-style accommodations designed for comfort and convenience. Our spacious studios and one-bedroom suites feature fully equipped kitchens, as well as separate living and sleeping areas—perfect for short or extended stays. Guests can begin each day with a complimentary hot breakfast, stay active in the 24/7 fitness center, and unwind at the outdoor pool or by the patio firepit. For those balancing work and travel, the hotel offers fast, complimentary Wi-Fi and ergonomic workspaces. On Wednesdays from 5:00 pm to 7:00 pm, guests are invited to enjoy a complimentary evening reception with drinks and light bites. The property also features a self-serve PourMyBeer station, where guests can purchase beer or wine by the ounce. Additional amenities include BBQ grills, a well-stocked Suite Shop for late-night snacks, and pet-friendly accommodations to ensure every guest—two or four-legged—feels at home.

Ideally located just one mile from the University of Central Florida and Central Florida Research Park, Homewood Suites by Hilton Orlando – UCF Area offers exceptional convenience for business and campus visitors alike. Concertgoers and sports fans will appreciate our proximity—just two miles—to Addition Financial Arena and FBC Mortgage Stadium. For those seeking retail therapy or dining experiences, Waterford Lakes Town Center is only two miles away. Guests looking to explore the greater Orlando area will find an abundance of restaurants, entertainment venues, and local attractions just minutes from the hotel.

Homewood Suites by Hilton Orlando – UCF Area is owned and operated by Buffalo Lodging Associates, LLC, a hotel management & development company. Buffalo Lodging Associates, in partnership with Benderson Properties, Inc., owns and operates hotels throughout Western New York, New Jersey, Ohio, Pennsylvania, Massachusetts, Connecticut, Rhode Island, and Florida. For more information about Buffalo Lodging Associates’ group of award-winning hotels, please visit www.buffalolodging.com. 

For more information or to make reservations, please visit Homewood Suites by Hilton Orlando – UCF Area or call 407.282.0067.

Buffalo Lodging Associates
Buffalo Lodging Associates is a community of welcoming, committed, and passionate associates driven to provide a best-in-class hospitality experience and operational excellence. We are at our best when our associates thrive within their community while simultaneously growing professionally and personally. Buffalo Lodging Associates, in partnership with Benderson Properties, LLC, owns and operates hotels New York, New England, New Jersey, Ohio, and Florida. The substantial achievements of our hotels can be attributed to maintaining the highest level of product quality through development, technology, and interior design, as well as having well-trained, courteous, and dedicated employees who understand and provide exceptional customer service. For more information about Buffalo Lodging Associates’ company culture or hotels, please visit www.buffalolodging.com.

About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 24 world-class brands comprising more than 8,400 properties and over 1.25 million rooms, in 140 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed over 3 billion guests in its more than 100-year history, was named the No. 1 World’s Best Workplace by Great Place to Work and Fortune and has been recognized as a global leader on the Dow Jones Sustainability Indices. Hilton has introduced industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the more than 210 million Hilton Honors members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy. With the free Hilton Honors app, guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit stories.hilton.com for more information, and connect with Hilton on Facebook, X, LinkedIn, Instagram and YouTube. 

About Homewood Suites by Hilton


Homewood Suites by Hilton
, Hilton’s upscale, award-winning, all-suite extended-stay hotel brand, has more than 540 pet-friendly locations across the U.S., Mexico, Canada and the Caribbean, with more than 150 properties in the pipeline. When traveling for extended or quick overnight stays, Homewood Suites offers inviting, spacious suites featuring separate living and sleeping areas, and fully equipped kitchens with full-size refrigerators for guests seeking home-like accommodations and value-driven amenities, including free hot breakfast and weekly Welcome Home Wednesday evening reception. Homewood Suites by Hilton is focused on guest satisfaction and stands behind each stay with its 100% Suite Assurance^® guarantee. Experience a positive stay at Homewood Suites by Hilton by booking at homewoodsuites.com or through the industry-leading Hilton Honors app. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits. Learn more about Homewood Suites by Hilton at stories.hilton.com/homewoodsuites, and follow the brand on Facebook and Instagram. 

CONTACT:

Connie Roberts

Marketing and Design Manager
Homewood Suites by Hilton
Orlando – UCF Area
716.878.9319
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/homewood-suites-by-hilton-orlando–ucf-area-enhances-guest-experience-with-comprehensive-renovation-302488395.html

SOURCE Buffalo Lodging Associates

For second consecutive year, Allegiant wins for its exceptional customer service

LAS VEGAS
, June 23, 2025 /PRNewswire/ — Allegiant Travel Company (NASDAQ: ALGT) has been named   2025’s Best Low-Cost Airline in North America by Skytrax, the international air transport rating organization. This is the second consecutive year Allegiant has won this award.

The Las Vegas-based airline received the recognition during Skytrax’s World Airline Awards ceremony held at the Paris Air Show in June. Known as the “Oscars of aviation,” the ceremony recognizes airlines around the world for outstanding customer service.

“It’s such an honor to receive this award once again,” said Allegiant’s Chief Executive Officer & President, Gregory C. Anderson. “We strive to provide our customers with a seamless, comfortable and convenient travel experience, and this recognition validates our efforts. As a leisure focused airline, our unique business model bridges the gap in connecting small-to-medium sized cities to premier vacation destinations. This accolade is a testament to the hard work of our team members and acknowledges Allegiant’s long history of providing exceptional service at unbeatable value for our customers.”

Founded with the mission to make air travel more accessible and convenient, Allegiant’s unique business strategy continues to reshape the U.S. leisure travel industry. Allegiant’s network of all-nonstop flights, serving communities often overlooked by other carriers, has been a key differentiator that separates the airline from others.

“Allegiant’s back-to-back recognition as North America’s best low-cost airline is a testament to its customer-focused approach. Passengers have highlighted the airline’s commitment to providing reliable, value-driven service tailored for leisure travelers,” said CEO of Skytrax, Edward Plaisted.

To determine the winners, Skytrax conducted the largest airline passenger satisfaction survey – collecting sentiment about airlines from travelers across the world, with 22.3 million surveys counted in the 2025 results. Research for the 2025 World Airline Awards was conducted between September 2024 and May 2025.

The World Airline Awards included survey participation from over 100 customer nationalities. Survey entries were screened to identify IP and user information, with all duplicate, suspect or ineligible entries deleted. Over 325 airlines are featured in the results.

To learn more about the World Airline Awards, click here.

Allegiant – Together We Fly^™

Las Vegas-based Allegiant (NASDAQ: ALGT) is an integrated travel company with an airline at its heart, focused on connecting customers with the people, places and experiences that matter most. Since 1999, Allegiant Air has linked travelers in small-to-medium cities to world-class vacation destinations with all-nonstop flights and industry-low average fares. Today, Allegiant serves communities across the nation, with base airfares less than half the cost of the average domestic roundtrip ticket. For more information, visit us at Allegiant.com. Media information, including photos, is available at http://gofly.us/iiFa303wrtF

Media Contact

Phone: 702-800-2020
Email: [email protected]

Category: News
Category: Inflight
Category: Routes

View original content to download multimedia:https://www.prnewswire.com/news-releases/allegiant-named-best-low-cost-airline-in-north-america-at-the-2025-world-airline-awards-302488392.html

SOURCE Allegiant Travel Company